1492 Capital Management Increases Position in Therapeuticsmd (TXMD); Connor Clark & Lunn Investment Management LTD Has Boosted Stake in Turkcell Iletisim Hizmetleri A.S. (Adr) (TKC) by $616,800

March 14, 2018 - By Evgen Dobrzhanskiy

1492 Capital Management Llc increased its stake in Therapeuticsmd Inc (TXMD) by 86.42% based on its latest 2017Q3 regulatory filing with the SEC. 1492 Capital Management Llc bought 181,115 shares as the company’s stock declined 24.96% while stock markets rallied. The institutional investor held 390,702 shares of the health care company at the end of 2017Q3, valued at $2.07 million, up from 209,587 at the end of the previous reported quarter. 1492 Capital Management Llc who had been investing in Therapeuticsmd Inc for a number of months, seems to be bullish on the $1.14B market cap company. The stock 0.09% or $0 during the last trading session, reaching $5.28. It is down 46.30% since March 14, 2017 and is downtrending. It has underperformed by 63.00% the S&P500.

Connor Clark & Lunn Investment Management Ltd increased its stake in Turkcell Iletisim Hizmetleri A.S. (Adr) (TKC) by 165.84% based on its latest 2017Q3 regulatory filing with the SEC. Connor Clark & Lunn Investment Management Ltd bought 77,100 shares as the company’s stock declined 1.71% while stock markets rallied. The institutional investor held 123,591 shares of the telecommunications equipment company at the end of 2017Q3, valued at $1.09 million, up from 46,491 at the end of the previous reported quarter. Connor Clark & Lunn Investment Management Ltd who had been investing in Turkcell Iletisim Hizmetleri A.S. (Adr) for a number of months, seems to be bullish on the $8.74B market cap company. The stock increased 3.44% or $0.33 during the last trading session, reaching $9.91. About 26,734 shares traded. Turkcell Iletisim Hizmetleri A.S. (NYSE:TKC) has declined 9.06% since March 14, 2017 and is downtrending. It has underperformed by 25.76% the S&P500.

Among 4 analysts covering TherapeuticsMD (NYSEMKT:TXMD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TherapeuticsMD had 6 analyst reports since September 21, 2015 according to SRatingsIntel. The stock of TherapeuticsMD, Inc. (NASDAQ:TXMD) has “Buy” rating given on Tuesday, November 22 by Jefferies. Oppenheimer initiated TherapeuticsMD, Inc. (NASDAQ:TXMD) on Tuesday, November 22 with “Outperform” rating. Stifel Nicolaus maintained TherapeuticsMD, Inc. (NASDAQ:TXMD) on Tuesday, December 8 with “Buy” rating. Jefferies maintained TherapeuticsMD, Inc. (NASDAQ:TXMD) on Monday, September 21 with “Buy” rating. Jefferies maintained the shares of TXMD in report on Tuesday, December 8 with “Buy” rating.

Investors sentiment increased to 1.73 in 2017 Q3. Its up 0.69, from 1.04 in 2017Q2. It increased, as 9 investors sold TXMD shares while 28 reduced holdings. 24 funds opened positions while 40 raised stakes. 162.04 million shares or 5.51% more from 153.57 million shares in 2017Q2 were reported. Metropolitan Life Insurance Company Ny invested in 0% or 102,975 shares. D E Shaw & Incorporated holds 0.01% in TherapeuticsMD, Inc. (NASDAQ:TXMD) or 709,290 shares. Landscape Capital Mngmt Ltd Liability Company owns 48,917 shares. Morgan Stanley holds 432,967 shares or 0% of its portfolio. Guggenheim Capital Ltd Liability stated it has 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD). 74,954 are held by State Board Of Administration Of Florida Retirement Sys. 11.12 million are owned by Blackrock Inc. Rock Springs Capital Lp holds 0.39% of its portfolio in TherapeuticsMD, Inc. (NASDAQ:TXMD) for 1.60 million shares. State Street Corp reported 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD). Fmr Ltd Limited Liability Company holds 0.02% or 29.20M shares in its portfolio. Perigon Wealth Management Ltd holds 0% or 100 shares in its portfolio. 51,532 are owned by Outfitter Advsrs. Bluecrest Mngmt reported 0% of its portfolio in TherapeuticsMD, Inc. (NASDAQ:TXMD). Ahl Prns Llp reported 11,708 shares or 0% of all its holdings. Citadel Advsrs Ltd Liability Com has 0% invested in TherapeuticsMD, Inc. (NASDAQ:TXMD) for 26,350 shares.

Among 3 analysts covering Turkcell (NYSE:TKC), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Turkcell had 4 analyst reports since September 3, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Thursday, September 3 by Bank of America. The stock of Turkcell Iletisim Hizmetleri A.S. (NYSE:TKC) earned “Overweight” rating by JP Morgan on Thursday, September 17. The stock of Turkcell Iletisim Hizmetleri A.S. (NYSE:TKC) has “Neutral” rating given on Wednesday, April 6 by JP Morgan. The firm has “Buy” rating given on Thursday, January 5 by Deutsche Bank.

Connor Clark & Lunn Investment Management Ltd, which manages about $26.75B and $16.66 billion US Long portfolio, decreased its stake in Agnc Investment Corp by 186,192 shares to 546,832 shares, valued at $11.86M in 2017Q3, according to the filing. It also reduced its holding in Amplify Snack Brands Inc by 223,291 shares in the quarter, leaving it with 836,109 shares, and cut its stake in Yamana Gold Inc. (NYSE:AUY).